News

The study shows that the diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.

Semaglutide, the active ingredient on weight loss drugs Wegovy and Ozempic, shows evidence that the drug may also help reduce the risks of heart disease.

The diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.

Grace Hoffman, Nutritional Coordinator with Saint Luke's Mid America Heart Institute and the Food As Medicine Everyday (FAME) program, shares healthy lunch options for kids and adults as school kicks off with the FOX4 morning show.

Weight-loss drug Wegovy (semaglutide) and its diabetes-focused cousin, Ozempic, have already upended the treatment of both obesity and diabetes, with sales of both drugs skyrocketing.

Asian individuals with out-of-hospital cardiac arrest have similar rates of bystander cardiopulmonary resuscitation as White individuals, but have lower survival rates, according to a new study.

Asian individuals experience poorer outcomes after out-of-hospital cardiac arrest in the U.S. compared with white individuals, despite similar rates of bystander CPR.

Grace Hoffman, nutritional coordinator with Saint Luke's Mid America Heart Institute and the Food As Medicine Everyday (FAME) program, shares a fun summer recipe with the FOX4 morning show.

Dr. Mikhail Kosiborod presented on the benefits of a cardiometabolic center of excellence for patients with cardiometabolic diseases at the ADA conference in San Diego.

Melissa Magwire talks about why diabetes is a population health problem and a unique program at Saint Luke's that is helping patients across the nation.